Health-related quality of life of multidrug-resistant tuberculosis patients: A study of eastern Uttar Pradesh, India

Indian J Tuberc. 2022 Jul;69(3):347-353. doi: 10.1016/j.ijtb.2021.06.002. Epub 2021 Jun 15.

Abstract

Introduction: Much attention has been given to the microbiological aspect, drug treatment, and clinical indicators of MDR-TB, but patients' QOL has remained a neglected area. In this study, we aimed to find the quality of MDRTB on various quality of life domains during the initiation of the MDR Treatment regimen.

Materials & methods: A cross-sectional study was conducted over a period of 6 months at the Drug-Resistance Tuberculosis Management Centre (DR-TB Centre), of a tertiary care centre in the eastern Uttar pradesh, India. Patients with age >18 years diagnosed with MDR-TB (Multidrug resistance TB) were included in the study. The WHO QOL-BREF scale was used to assess the health-related quality of life of patients. Data were analyzed using SPSS version 21. The institutional ethical review committee approved the study, and consent was taken before the participation of patients.

Results: A total of 157 patients were included in the study & 45.85% were dissatisfied with their condition. Social domain of WHO QOL-BREF is having the lowest mean score (28.51 ± 15.4) while psychological has high mean values (39.92 ± 6.91). There was a significant difference in the physical health domain with respect to age (p-value 0.001). Similar differences have been seen in the psychological domain regarding patient sex (p-value 0.001), smoking and alcohol within the social domain, and loss of income in the environmental domain.

Conclusion: The mean value of different domains of WHO QOL-BREF is low in MDR-TB patients, with social relation domain being the most affected.

Keywords: MDR-TB; Multidrug resistance tuberculosis; Quality of life; Tuberculosis.

MeSH terms

  • Adolescent
  • Antitubercular Agents / therapeutic use
  • Cross-Sectional Studies
  • Humans
  • Income
  • India / epidemiology
  • Mycobacterium tuberculosis*
  • Quality of Life
  • Tuberculosis, Multidrug-Resistant* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / epidemiology

Substances

  • Antitubercular Agents